Stoke Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference

Rhea-AI Summary

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology firm focused on RNA-based therapies for severe diseases, will present at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 9:10 a.m. ET. The event will be accessible via a live webcast on their official website, with a replay available for 30 days. Stoke utilizes its innovative TANGO approach to develop targeted treatments, such as STK-001 for Dravet syndrome and STK-002 for autosomal dominant optic atrophy. The company is headquartered in Bedford, Massachusetts.

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will participate on the Orphan Neuro Panel at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 9:10 a.m. ET.

A live webcast will be available on the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/, or by clicking here. A replay of the webcast will be available for 30 days following the event.

About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke’s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow Stoke on Twitter at @StokeTx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005161/en/

Stoke Investor Contact:

Eric Rojas

Vice President, Investor Relations

IR@stoketherapeutics.com

617-312-2754

Source: Stoke Therapeutics, Inc.

FAQ

What event will Stoke Therapeutics participate in on March 7, 2022?

Stoke Therapeutics will participate in the Cowen 42nd Annual Health Care Conference.

What time will Stoke present at the Cowen conference?

Stoke Therapeutics is scheduled to present at 9:10 a.m. ET.

Where can I watch the Stoke Therapeutics presentation?

The presentation will be available via a live webcast on Stoke's investor website.

What is the main focus of Stoke Therapeutics?

Stoke Therapeutics focuses on upregulating protein expression to address severe diseases with RNA-based medicines.

What drugs is Stoke Therapeutics developing?

Stoke is developing STK-001 for Dravet syndrome and STK-002 for autosomal dominant optic atrophy.